Marcelle G. Meseeha

Internal Medicine
1 Guthrie Sq
Sayre, PA 18840

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

HSR26-227: Post-Allogenic Hematopoietic Stem Cell Transplant (Allo-HSCT), Hypomethylating-Agent Maintenance Improves Survival Without Increasing GVHD (Graft Versus Host Disease) in AML/MDS (Acute Myeloid Leukemia/Myelodysplastic Syndrome): Updated Systematic Review and Meta-Analysis.

HSR26-227: Post-Allogenic Hematopoietic Stem Cell Transplant (Allo-HSCT), Hypomethylating-Agent Maintenance Improves Survival Without Increasing GVHD (Graft Versus Host Disease) in AML/MDS (Acute Myeloid Leukemia/Myelodysplastic Syndrome): Updated Systematic Review and Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 30, 2026

HSR26-241: Prophylactic G-CSF (Granulocyte Colony-Stimulating Factor) in AML (Acute Myeloid Leukemia) Induction: A Meta-Analysis Dispelling Relapse Concerns and Reinforcing Supportive Benefit.

HSR26-241: Prophylactic G-CSF (Granulocyte Colony-Stimulating Factor) in AML (Acute Myeloid Leukemia) Induction: A Meta-Analysis Dispelling Relapse Concerns and Reinforcing Supportive Benefit.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026

HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.

HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 31, 2026

HSR26-241: Prophylactic G-CSF (Granulocyte Colony-Stimulating Factor) in AML (Acute Myeloid Leukemia) Induction: A Meta-Analysis Dispelling Relapse Concerns and Reinforcing Supportive Benefit.

HSR26-241: Prophylactic G-CSF (Granulocyte Colony-Stimulating Factor) in AML (Acute Myeloid Leukemia) Induction: A Meta-Analysis Dispelling Relapse Concerns and Reinforcing Supportive Benefit.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

HSR26-227: Post-Allogenic Hematopoietic Stem Cell Transplant (Allo-HSCT), Hypomethylating-Agent Maintenance Improves Survival Without Increasing GVHD (Graft Versus Host Disease) in AML/MDS (Acute Myeloid Leukemia/Myelodysplastic Syndrome): Updated Systematic Review and Meta-Analysis.

HSR26-227: Post-Allogenic Hematopoietic Stem Cell Transplant (Allo-HSCT), Hypomethylating-Agent Maintenance Improves Survival Without Increasing GVHD (Graft Versus Host Disease) in AML/MDS (Acute Myeloid Leukemia/Myelodysplastic Syndrome): Updated Systematic Review and Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.

HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

Parenteral replacement therapy with iron dextran or ferumoxytol in patients with iron deficiency.

Parenteral replacement therapy with iron dextran or ferumoxytol in patients with iron deficiency.

Journal: International journal of clinical pharmacology and therapeutics
Published: December 30, 2025

Metachronous gastro-oesophageal adenocarcinoma in a patient with colon adenocarcinoma.

Metachronous gastro-oesophageal adenocarcinoma in a patient with colon adenocarcinoma.

Journal: BMJ case reports
Published: April 08, 2025

Platelet levels before and after iron replacement therapy in patients with iron deficiency anemia.

Platelet levels before and after iron replacement therapy in patients with iron deficiency anemia.

Journal: Hematology (Amsterdam, Netherlands)
Published: February 07, 2025

Venous thromboembolism in patients with hairy cell leukemia.

Venous thromboembolism in patients with hairy cell leukemia.

Journal: Hematology (Amsterdam, Netherlands)
Published: November 27, 2024
Showing 1-12 of 20

Last Updated: 09/26/2026